Patritumab deruxtecan, which is currently leading the anti-HER3 pipeline, has shown efficacy in heavily pre-treated patients with EGFR-mutated NSCLC previously treated with multiple EGFR ...

Patritumab deruxtecan starts phase 3 Daiichi ... second-line therapy for EGFR-mutated advanced non-squamous NSCLC. The HER3-directed ADC will be tested in patients whose disease had progressed ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals ...